Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2024-06-27 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-06-27 English
Otra información relevante.
Capital/Financing Update Classification · 95% confidence The document is a formal communication from Grifols, S.A., titled 'OTHER RELEVANT INFORMATION' and issued pursuant to Spanish securities law (article 227 of Law 6/2023). It provides specific updates regarding debt reduction (SSNs, TLBs, SUNs), expected leverage ratios, liquidity position, and Free Cash Flow (FCF) guidance for FY24 and FY25. This content relates to the company's financial health, capital structure, and recent transactions (SRAAS sale proceeds). It is not a full annual report (10-K), an earnings release (ER) with only highlights, or a formal presentation (IP). It is a specific, material financial update that doesn't fit perfectly into the defined categories like 'Capital/Financing Update' (CAP) or 'Interim Report' (IR), as it is more of a targeted disclosure following media/rating agency news. Given the nature of providing specific financial metrics, debt repayment plans, and liquidity updates outside of a standard quarterly/annual report structure, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous, material disclosure, or potentially 'CAP' if the focus is heavily on debt structure changes. However, since it is a direct disclosure of material financial status updates and debt management following external events, and not a standard periodic report, RNS is the most appropriate fallback for specific, non-standard material information disclosures.
2024-06-27 English
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a Director (Thomas Glanzmann, Presidente Ejecutivo) in the company's shares. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Type Code mapping: - AGM-R: No (Not AGM material). - 10-K: No (Not Annual Report). - AR: No (Not Audit Report). - MANG: No (Not management change). - CT: No (Not Call Transcript). - CAP: No (Not financing). - DVA: No (Not voting results). - DLST: No (Not delisting). - DIRS: Yes (Director's Dealing/Insider Trade notification). - ER: No (Not earnings release). - SR: No (Not ESG). - XLSX: No (Not Excel data). - FS: No (Not factsheet). - CGR: No (Not governance). - IRAT: No (Not interest rate). - IR: No (Not interim report). - IP: No (Not investor presentation). - LTR: No (Not legal). - TAR: No (Not M&A). - MRQ: No (Not major shareholding change, this is director-specific). - MDA: No (Not management discussion). - NAV: No (Not NAV). - DIV: No (Not dividend). - PSI: No (Not proxy solicitation). - RNS: No (More specific category exists). - DEF 14A: No (Not remuneration report). - RPA: No (This is the filing itself, not an announcement of a filing). - SHA: No (Not general share issue). - POS: No (Not company buying back its own shares; this is an insider transaction). The correct classification is DIRS (Director's Dealing). The document length (4033 chars) is sufficient to contain the details, so the RPA/RNS rule does not apply.
2024-06-21 Spanish
FORM 6-K
Regulatory Filings
2024-06-18 English
Grifols informa del cierre de la transacción en China con Haier Group Corporation.
M&A Activity Classification · 99% confidence The document is a formal communication from Grifols, S.A., referencing Spanish securities law (artículo 227 de la Ley 6/2023) and explicitly stating it is communicating 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It details the closing of a previously announced Strategic Alliance and Share Purchase Agreement concerning a stake in SRAAS to Haier Group. This type of material, non-periodic, price-sensitive information disclosed outside of standard quarterly or annual reports, typically falls under general regulatory disclosure requirements. Since it is not a specific report (like 10-K, IR, ER), nor a management change (MANG), nor a director's dealing (DIRS), nor a dividend notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings), as it is a mandatory disclosure of a significant corporate transaction closing.
2024-06-18 Spanish
FORM 6-K
Regulatory Filings
2024-06-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.